Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study

Abstract

Background: Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disease whose primary clinical manifestation is bilateral visual loss. Only a single therapy, idebenone, is approved in Europe for use in exceptional circumstances and no therapy is currently approved in the USA. LHON remains a disease with a high unmet medical need.

Objective: This is a report of an open-label, single-center, dose-escalation study that evaluated the safety and tolerability of lenadogene nolparvovec in 15 subjects with LHON for up to 5 years following a single intravitreal injection at four dose levels.

Methods: Subjects were enrolled sequentially in four cohorts followed by an additional cohort at the dose selected, and safety was assessed by an independent data safety monitoring board (DSMB) prior to any dose escalation.

Results: Overall, the treatment was well tolerated during the 5-year follow-up. No serious adverse events were considered related to treatment, no unexpected adverse events occurred, and no grade 3 or 4 Common Terminology Criteria for Adverse Events were reported. Anterior chamber inflammation and vitritis were mostly managed with topical steroids, and ocular inflammation was considered to be dose limiting by the DSMB based on the benefits/risks for the subjects. Analysis of the logarithm of the minimal angle of resolution (LogMAR) visual acuity in both treated and untreated eyes showed clinically relevant and durable improvements compared with baseline. Mean improvements of - 0.44 and - 0.49 LogMAR for treated and untreated eyes, respectively, were noted, with a mean (± standard deviation) final value of LogMAR + 1.96 ± 0.60 and + 1.65 ± 0.34, respectively, at 5 years post-treatment administration. For the six subjects treated with the optimal dose level (9 × 10¹⁰ viral genomes [vg]/eye), the mean visual acuity improvement from baseline reached - 0.68 LogMAR for treated eyes and - 0.64 LogMAR for untreated eyes, with a mean final value of LogMAR + 1.77 ± 0.52 and + 1.78 ± 0.34, respectively. While there was a meaningful improvement in visual acuity for REVEAL subjects, the final visual acuity was less favorable than that seen in the two subsequent pivotal phase III studies in which subjects were treated earlier during the course of their disease.

Conclusion: Lenadogene nolparvovec was well tolerated with a good safety profile during 5 years of follow-up and may offer meaningful lasting improvements in vision for this LHON population.

Clinical trial number: EUDRACT N° 2013-001405-90.

Fig. 1

Disposition of subjects. DSMB data safety monitoring board, vg viral genomes

Fig. 2

Mean LogMAR scores from baseline at each visit to year 5 for all treated eyes. Cohort 1: 9 × 10⁹ vg/eye; cohort 2: 3 × 10¹⁰ vg/eye; cohorts 3 and 5: 9 × 10¹⁰ vg/eye; cohort 4: 1.8 × 10¹¹ vg/eye. LogMAR logarithm of the minimal angle of resolution, vg viral genomes

Fig. 3

Mean change in LogMAR from baseline at each visit to year 5 for all treated eyes. Cohort 1: 9 × 10⁹ vg/eye; cohort 2: 3 × 10¹⁰ vg/eye; cohorts 3 and 5: 9 × 10¹⁰ vg/eye; cohort 4: 1.8 × 10¹¹ vg/eye. LogMAR logarithm of the minimal angle of resolution, vg viral genomes

Fig. 4

Mean LogMAR scores at each visit and for both treated and untreated eyes at the 9 × 10¹⁰ vg/eye dose. LogMAR logarithm of the minimal angle of resolution, vg viral genomes

Fig. 5

Mean change of LogMAR at each visit for both treated and untreated eyes at the 9 × 10¹⁰ vg/eye dose. LogMAR logarithm of the minimal angle of resolution, vg viral genomes